Stock Market News
Shire and ABB strike deal to develop and commercialize autoimmune diseases treatment
Shire Pharmaceuticals and AB Biosciences have struck a deal to develop and commercialise ABB's PRIM Program to treat autoimmune diseases and other immune-mediated disorders.
Shire will receive the exclusive worldwide license to develop and commercialise intellectual property from the program, paying ABB a license fee and potential research, development and commercial milestone payments.
The PRIM program is a novel protein therapeutic for the treatment of autoimmune disorders and inflammatory diseases. It has shown encouraging preclinical data, including enhanced biological activity relative to currently approved intravenous immunoglobulin therapies in pre-clinical models.
"This agreement provides the opportunity to accelerate the development of the PRIM program and potentially benefit patients with autoimmune and inflammatory disorders that are currently treated with the traditional human IVIg preparations," said Yen-Ming Hsu, ABB's president and chief executive officer.
"As a global biotech leader in the development and commercialization of biologic therapeutics, Shire is the ideal development and commercialization partner for our innovative PRIM program, particularly given their proven developmental expertise and continuing success in their IVIg commercial franchise."
Andreas Busch, Head of Research and Development and Chief Scientific Officer at Shire said, "AB Biosciences has demonstrated innovation in the area of antibody technology and protein design, and Shire is pleased to continue to advance this program."
"The novel design of this investigational antibody-derived recombinant protein therapeutic and promising biological activity demonstrated in preclinical models makes the PRIM program an exciting opportunity for Shire to further expand its leadership and commitment to treating patients with autoimmune disorders," he added.
Shire will receive the exclusive worldwide license to develop and commercialise intellectual property from the program, paying ABB a license fee and potential research, development and commercial milestone payments.
The PRIM program is a novel protein therapeutic for the treatment of autoimmune disorders and inflammatory diseases. It has shown encouraging preclinical data, including enhanced biological activity relative to currently approved intravenous immunoglobulin therapies in pre-clinical models.
"This agreement provides the opportunity to accelerate the development of the PRIM program and potentially benefit patients with autoimmune and inflammatory disorders that are currently treated with the traditional human IVIg preparations," said Yen-Ming Hsu, ABB's president and chief executive officer.
"As a global biotech leader in the development and commercialization of biologic therapeutics, Shire is the ideal development and commercialization partner for our innovative PRIM program, particularly given their proven developmental expertise and continuing success in their IVIg commercial franchise."
Andreas Busch, Head of Research and Development and Chief Scientific Officer at Shire said, "AB Biosciences has demonstrated innovation in the area of antibody technology and protein design, and Shire is pleased to continue to advance this program."
"The novel design of this investigational antibody-derived recombinant protein therapeutic and promising biological activity demonstrated in preclinical models makes the PRIM program an exciting opportunity for Shire to further expand its leadership and commitment to treating patients with autoimmune disorders," he added.
Related share prices |
---|
Shire Plc (SHP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price